Bacillus subtilis PXN21 is a type of beneficial bacteria commonly found in the gut. There is evidence to suggest that the gut microbiome, which includes a diverse community of microorganisms that live in the digestive tract, plays a key role in Parkinson’s. Some studies have shown that people with Parkinson’s have different gut microbiome compositions compared with healthy individuals.
This study is investigating the effects of B. Subtilis PXN21 on the gut microbiome in people with Parkinson’s. The study is recruiting participants with Parkinson’s and randomly assigning them to either a treatment group or a placebo group. The treatment group will receive B. Subtilis PXN21 in the form of a pill supplement, while the placebo group will receive a similar-looking and tasting product that does not contain the bacteria.
During the study, researchers will collect stool samples from both groups of participants to analyse changes in gut microbiome composition. They will also assess clinical features of Parkinson’s such as changes in motor symptoms, cognitive function, and daily living.
The goal of this study is to find out whether B. Subtilis PXN21 has beneficial effects on gut microbiome composition or Parkinson’s symptoms. If the results are promising, this could lead to the development of new treatments for Parkinson’s that target the gut microbiome.
Image credit: nopparit via Getty images
